PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Targeted therapy - Market size and forecast 2018-2023 • Immunotherapy - Market size and forecast 2018-2023 • Chemotherapy - Market size and forecast 2018-2023 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb Company • Eli Lilly and Company • F. Hoffmann-La Roche Ltd • Merck & Co., Inc. • Sanofi PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Type - Market share 2018-2023 (%) Exhibit 18: Comparison by type Exhibit 19: Targeted therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Targeted therapy - Year-over-year growth 2019-2023 (%) Exhibit 21: Targeted therapies in Phase III for colorectal cancer treatment Exhibit 22: Immunotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Immunotherapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Colorectal cancer rate based on gender in US 2015 Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in North America Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Europe - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Europe Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Asia Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in ROW Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Rate of colorectal cancer by age in the US Exhibit 46: Global geriatric population Exhibit 47: Combination therapies for colorectal cancer treatment Exhibit 48: Late-stage combination therapies for treatment of colorectal cancer Exhibit 49: Estimated patent expiry dates of a few therapeutics used for colorectal cancer treatment Exhibit 50: Impact of drivers and challenges Exhibit 51: Some of the kinase inhibitors under development for colorectal cancer treatment Exhibit 52: Vendor landscape Exhibit 53: Landscape disruption Exhibit 54: Vendors covered Exhibit 55: Vendor classification Exhibit 56: Market positioning of vendors 0 Exhibit 57: Bristol-Myers Squibb Company - Vendor overview 1 Exhibit 58: Bristol-Myers Squibb Company - Business segments 1 Exhibit 59: Bristol-Myers Squibb Company - Organizational developments 2 Exhibit 60: Bristol-Myers Squibb Company - Geographic focus 3 Exhibit 61: Bristol-Myers Squibb Company - Key offerings 4 Exhibit 62: Bristol-Myers Squibb Company - Key customers 4 Exhibit 63: Eli Lilly and Company - Vendor overview 5 Exhibit 64: Eli Lilly and Company - Business segments 5 Exhibit 65: Eli Lilly and Company - Organizational developments 6 Exhibit 66: Eli Lilly and Company - Geographic focus 7 Exhibit 67: Eli Lilly and Company - Segment focus 7 Exhibit 68: Eli Lilly and Company - Key offerings 7 Exhibit 69: Eli Lilly and Company - Key customers 8 Exhibit 70: F. Hoffmann-La Roche Ltd - Vendor overview 9 Exhibit 71: F. Hoffmann-La Roche Ltd - Business segments 9 Exhibit 72: F. Hoffmann-La Roche Ltd - Organizational developments 0 Exhibit 73: F. Hoffmann-La Roche Ltd - Geographic focus 1 Exhibit 74: F. Hoffmann-La Roche Ltd - Segment focus 1 Exhibit 75: F. Hoffmann-La Roche Ltd - Key offerings 2 Exhibit 76: F. Hoffmann-La Roche Ltd - Key customers 2 Exhibit 77: Merck & Co., Inc. - Vendor overview 3 Exhibit 78: Merck & Co., Inc. - Business segments 3 Exhibit 79: Merck & Co., Inc. - Organizational developments Exhibit 80: Merck & Co., Inc. - Geographic focus Exhibit 81: Merck & Co., Inc. - Segment focus Exhibit 82: Merck & Co., Inc. - Key offerings Exhibit 83: Merck & Co., Inc. - Key customers Exhibit 84: Sanofi - Vendor overview Exhibit 85: Sanofi - Business segments Exhibit 86: Sanofi - Organizational developments Exhibit 87: Sanofi - Geographic focus Exhibit 88: Sanofi - Segment focus Exhibit 89: Sanofi - Key offerings Exhibit 90: Sanofi - Key customers Exhibit 91: Validation techniques employed for market sizing  

Bristol-Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd Merck & Co. Inc. Sanofi